Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial
| Autor: | John T. Carpenter, Edwin B. Cox, Charles L. Vogel, Marilyn Raney |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Drug Resistance Phases of clinical research Breast Neoplasms Breast cancer Internal medicine medicine Humans Pharmacology (medical) Neoplasm Metastasis Aged Podophyllotoxin Teniposide Pharmacology business.industry Cancer Middle Aged medicine.disease Metastatic breast cancer Toxicity Every Three Weeks Drug Evaluation Female Breast carcinoma business medicine.drug |
| Zdroj: | Investigational new drugs. 6(1) |
| ISSN: | 0167-6997 |
| Popis: | The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink